ライフサイエンスコーパス: troponin T

1 patients for troponin I and 25 patients for troponin T).

2 relate with log(concomitant high-sensitivity troponin-T).

3 syndrome (NSTE-ACS) and an elevated cardiac troponin T.

4 tients with NSTE-ACS and an elevated cardiac troponin T.

5 by a positive test for cardiac troponin I or troponin T.

6 ned changes in pre-dialysis highly sensitive troponin T.

7 asmic reticulum Ca(2+) ATPase 1, and cardiac troponin T.

8 an Nkx2.5-LacZ reporter and upregulation of troponin T.

9 tients with NSTE-ACS and an elevated cardiac troponin T.

10 tality, better than high-sensitivity cardiac troponin T.

11 terminal pro-B-type natriuretic peptide, and troponin T.

12 detecting low concentrations of the protein troponin-T.

13 ated by the significantly reduced release of troponin-T.

14 system was developed that used thresholds of troponin T (0.05 ng/ml) and N-terminal pro-B-type natriu

15 se without (n = 43) (mean +/- SD increase in troponin T, 0.011 +/- 0.009 vs. 0.003 +/- 0.006 mug/L, P

16 ients with elevated high-sensitivity cardiac troponin T, 31 had signs of MI and 113 did not.

17 Levels of cardiac troponin T, a biomarker of cardiomyocyte injury, were me

18 ity C-reactive protein, and high-sensitivity troponin T, Abeta40 independently predicted CV death and

19 Adding high-sensitive cardiac troponin T absolute change to the Revised Cardiac Risk I

20 The high-sensitivity troponin T algorithm ruled out 1425 (64.1%) with a sensi

21 equivalent were 3.0 (95% CI, 2.4 to 4.3) for troponin T and 2.7 (CI, 1.9 to 4.6) for troponin I.

22 ular mortality were 3.3 (CI, 1.8 to 5.4) for troponin T and 4.2 (CI, 2.0 to 9.2) for troponin I.

23 expression of cardiomyogenic markers cardiac troponin T and alpha-smooth muscle actin in CPCedeltaB c

24 ins, including myosin light chain-2 slow and troponin T and carbonylation of myosin heavy chains.

25 easurement of the cardiac troponins, cardiac troponin T and cardiac troponin I, using sensitive metho

26 the duration of such therapy, the levels of troponin T and creatine kinase, and the rates of bleedin

27 High-sensitivity cardiac troponin T and creatine kinase-myocardial band were meas

28 is of two meat tenderisation protein markers troponin T and desmin by the four proteases was detected

29 Serum levels of troponin T and heart-type fatty acid binding protein wer

30 e 2222 patients with serial high-sensitivity troponin T and high-sensitivity troponin I measurements.

31 and serial plasma levels of high-sensitivity troponin T and midregional proatrial natriuretic peptide

32 l-known biomarkers (high-sensitivity cardiac troponin T and N-terminal pro-brain natriuretic peptide)

33 s ECG for 48 hours perioperatively, measured troponin T and N-terminal prohormone of brain natriureti

34 pomyosin alpha-1 chain, fast myotomal muscle troponin T and parvalbumin beta 2 increased their intens

35 beating sheets of cells that express cardiac troponin T and show a full range of action potential mor

36 th chest pain, evaluating them with standard troponin T and testing for hs-cTnT (Roche Diagnostics, B

37 ity C-reactive protein, and high-sensitivity troponin T and their changes.

38 Troponin-T and creatine kinase-MB peaked at day 1 after

39 Ln hs-CRP elevation correlated with Ln Troponin-T and fibrinogen elevation.

40 ssociated with high plasma concentrations of troponin-T and N-terminal brain natriuretic propeptide,

41 The orientation of troponin-T and the troponin core domain established trop

42 Cardiac Troponins (T and I) are well established protein biomark

43 late resulted in a lower heart rate, a lower troponin T, and a greater urine output as compared with

44 enaline, lipopolysaccharide binding protein, troponin T, and brain natriuretic peptide levels were me

45 d on clinical presentation, high-sensitivity troponin T, and cardiac magnetic resonance imaging, afte

46 mmetrical dimethylarginine, high-sensitivity troponin T, and cystatin C.

47 N-terminal pro-brain natriuretic peptide and Troponin T, and functional assessment comprising the 6-m

48 atriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive protein sign

49 atriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive protein.

50 nalyses, including C-reactive protein, IL-6, troponin T, and N-terminal pro-B-type natriuretic peptid

51 The extent of Ln hs-CRP, Ln Troponin-T, and fibrinogen elevation predicted early AF

52 Elevated levels of NT-proBNP, high-sensitive troponin-T, and growth-differentiation factor 15 identif

53 riuretic peptide (NT-proBNP), high-sensitive troponin-T, and growth-differentiation factor 15 with ca

54 arker measurement (NT-proBNP, high-sensitive troponin-T, and growth-differentiation factor 15) at the

55 rapid fall in pH, and rise in blood lactate, troponin-T, and potassium.

56 f N-terminal pro-B-type natriuretic peptide, troponin-T, and urinary albumin excretion, increasing mo

57 Very low levels of cardiac troponin T are associated with an increased risk of card

58 Very low but detectable levels of cardiac troponin T are associated with total CVD and CVD death i

59 iuretic peptide and high-sensitivity cardiac troponin T are frequently elevated in severe sepsis or s

60 in natriuretic peptide]), and myocyte death (troponin T) are related to anemia in HFrEF.

61 nine, among other parameters, and used serum troponin T as an index of myocardial injury.

62 rence limit for the high-sensitivity cardiac troponin T assay (hs-cTnT) in 3 large independent cohort

63 tested with a precommercial high-sensitivity troponin T assay (hsTnT) and compared with a conventiona

64 The TRAPID-AMI trial study (High-Sensitivity Troponin-T Assay for Rapid Rule-Out of Acute Myocardial

65 the widespread use of high-sensitive cardiac troponin T assays, positive tests become frequent, but t

66 urve for the high-sensitivity assay of serum troponin T at 72 hours), inotrope score (calculated from

67 stable angina (28% of patients) and negative Troponin T at baseline to 3 groups: 2 groups received RI

68 val incremental change of the ln-transformed troponin-T at 72 h was 0.79 +/- 1.54 in the xenon group

69 Postarrival incremental change in troponin-T at 72 hours was significantly less in the Xen

70 scularization (P<0.01), presence of elevated troponin T before the procedure (P<0.01), and peripheral

71 as by detecting different concentrations of Troponin T biomarkers (cTnT) through antibody-functional

72 L and a perioperative high-sensitive cardiac troponin T change greater than or equal to 6.3 ng/L are

73 k predictive power of high-sensitive cardiac troponin T change in addition to the Revised Cardiac Ris

74 osite end point in patients with an abnormal troponin T concentration (>/=14 ng per liter) as compare

75 liter) as compared with those with a normal troponin T concentration (<14 ng per liter).

76 We tested for an association between the troponin T concentration and a composite end point of de

77 We measured the cardiac troponin T concentration at baseline with a high-sensiti

78 The cardiac troponin T concentration was an independent predictor of

79 7 (99.6%) had detectable (>/=3 ng per liter) troponin T concentrations and 897 (39.3%) had abnormal t

80 7.1% among the patients who had had abnormal troponin T concentrations at baseline, as compared with

81 concentrations and 897 (39.3%) had abnormal troponin T concentrations at baseline.

82 osite end point among patients with abnormal troponin T concentrations was 1.85 (95% confidence inter

83 riuretic peptide or high-sensitivity cardiac troponin T concentrations were independently associated

84 Plasma troponin T concentrations were prospectively collected w

85 Among patients with abnormal troponin T concentrations, random assignment to prompt r

86 2.9% among those who had had normal baseline troponin T concentrations.

87 log-transformed concomitant high-sensitivity troponin-T concentrations (mixed linear model: t = 3.8,

88 ating best with concomitant high-sensitivity troponin-T concentrations.

89 Using Troponin T-Cre;CyclinA2-LacZ-EGFP mice, we examined card

90 o perform multiplexed detection of 100 fg/ml troponin T, creatine kinase MM, and creatine kinase MB i

91 flammatory markers included high-sensitivity troponin T, creatine kinase, myoglobin, N-terminal B-typ

92 igh-sensitivity C-reactive protein (hs-CRP), Troponin-T, creatine kinase-MB, fibrinogen, and D-Dimer

93 ty and changes in levels of highly sensitive troponin T (cTnT) and N-terminal pro-B-type natriuretic

94 Cardiac troponin T (cTnT) and sensitive cardiac troponin I (s-cT

95 Detectable levels of cardiac troponin T (cTnT) are strongly associated with structura

96 mine whether there is immunoreactive cardiac troponin T (cTnT) expression in diseased skeletal muscle

97 Abstract Cardiac troponin T (cTnT) has a highly acidic extended N-terminu

98 biological significance of elevated cardiac troponin T (cTnT) in patients with neuromuscular disease

99 Cardiac troponin T (cTnT) is a key component of contractile regu

100 Changes in cardiac troponin T (cTnT) levels are required for the diagnosis

101 assumption that chronically elevated cardiac troponin T (cTnT) levels fluctuate randomly around a hom

102 Elevated plasma cardiac troponin T (cTnT) levels in patients with neuromuscular

103 Serum creatine kinase-MB (CK-MB) and cardiac troponin T (cTnT) levels were measured before and after

104 We evaluated whether cardiac troponin T (cTnT) measured with a new highly sensitive a

105 p device provides the capability for cardiac-troponin T (cTnT) measurements with co-existed 10 microg

106 A novel double deletion in cardiac troponin T (cTnT) of two highly conserved amino acids (A

107 minate ischemia from other causes of cardiac troponin T (cTnT) release.

108 point was 48-hour area under the curve (AUC) troponin T (cTnT) release.

109 n a screen-printed electrode for the cardiac troponin T (cTnT) was developed.

110 udy was to evaluate whether elevated cardiac troponin T (cTnT) was independently associated with an i

111 epeated measures of highly sensitive cardiac troponin T (cTnT) were obtained in participants of the C

112 ry are cardiac troponin I (cTnI) and cardiac troponin T (cTnT) which have been considered as 'gold st

113 detector for an on-chip detection of cardiac troponin T (cTnT) with a detection limit of 12 pg/mL.

114 lacrylamide (PNIPAAm) functionalised cardiac troponin T (cTnT) with anti-cTnT.

115 of TNNT2, the gene that encodes for cardiac troponin T (cTnT), a biomarker of myocardial injury.

116 tion between LVH, low but detectable cardiac troponin T (cTnT), and elevated N-terminal pro-B-type na

117 Cardiac troponin T (cTnT), even at low concentrations, is a risk

118 eric/cooperative mechanism is cardiac muscle troponin T (cTnT), the central region (CR) and the T2 re

119 Cardiac troponin T (cTnT), the tropomyosin binding subunit of th

120 5, or that of the myocardial marker, cardiac troponin T (cTnT).

121 farction, especially with the use of cardiac troponin T (cTnT).

122 c AKAP (A-kinase anchoring protein), cardiac troponin T (cTnT).

123 factor-15 (GDF-15), high-sensitivity cardiac troponin T (cTnT-hs) and haemoglobin, age, and previous

124 ams and serial serum measurements of cardiac troponin T (cTnT; cardiac injury biomarker), N-terminal

125 ologic free light chains (p < 0.05), cardiac troponin-T (cTnT) (p < 0.01), and the Karnofsky index (p

126 lassification is based on cardiac biomarkers troponin-T (cTnT) and N-terminal pro-B-type natriuretic

127 ing of cardiac Troponin-I (cTnI) and cardiac-Troponin-T (cTnT) in a point-of-care sensor format.

128 the detection and quantification of cardiac Troponin-T (cTnT).

129 Pretransplant cardiac troponin T(cTnT(pre) ) is a significant predictor of sur

130 whereas the dilated cardiomyopathy mutation, troponin T DeltaK210, decreased the Ca(2+) sensitivity o

131 Elevated cardiac troponin T even below traditional detection levels can b

132 r reference limit and in NSTEMI as a pre-PCI troponin T fall, followed by post-PCI troponin T rise >2

133 The sensitivity of troponin T for ACS diagnosis ranged from 71% to 100%, an

134 ificantly from those of fast skeletal muscle troponin T (fsTnT).

135 gh impedance spectroscopy was used to detect troponin-T functionalized immunoassays on nanotextured Z

136 ity C-reactive protein, and high-sensitivity troponin T, GDF-15 remained independently associated wit

137 omyopathy caused by mutations in the cardiac troponin T gene (TNNT2) has been associated with a high

138 d syndrome and long-QT syndrome, and cardiac troponin T gene, tnnt2, affected in human cardiomyopathi

139 A preoperative high-sensitive cardiac troponin T greater than or equal to 17.8 ng/L and a peri

140 proBNP (>14 pmol/L), elevated high-sensitive troponin-T (>14 ng/L), and elevated growth-differentiati

141 Troponin-T, high-sensitive C-reactive protein, urinary a

142 uretic peptide, and high-sensitivity cardiac troponin T, higher levels of Cp were associated with HF

143 r circulation and a high-sensitivity cardiac troponin T (hs-cTnT) acquired on the day of admission.

144 ial measurements of high-sensitivity cardiac troponin T (hs-cTnT) and future events in HF.

145 h small elevations of high-sensitive cardiac troponin T (hs-cTnT) are associated with incident heart

146 High-sensitivity assays for cardiac troponin T (hs-cTnT) are sometimes used to rapidly rule

147 evel, with elevated high-sensitivity cardiac troponin T (hs-cTnT) concentrations (>/=14 ng/L) using P

148 ide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) concentrations were measured by ele

149 c value of baseline high-sensitivity cardiac troponin T (hs-cTnT) elevation in SCAD patients undergoi

150 oglobin (HbA1c) and high-sensitivity cardiac troponin T (hs-cTnT) in 9,661 participants free of CHD a

151 o mental stress and high-sensitivity cardiac troponin T (hs-cTnT) in healthy older individuals withou

152 cremental prognostic value of high-sensitive troponin T (hs-cTnT) in heart failure (HF) beyond that o

153 ions of introducing high-sensitivity cardiac troponin T (hs-cTnT) into clinical practice and to defin

154 High-sensitivity cardiac troponin T (hs-cTnT) is a biomarker of cardiovascular ri

155 etectable (<5 ng/l) high-sensitivity cardiac troponin T (hs-cTnT) level and an electrocardiogram (ECG

156 that any detectable high-sensitivity cardiac troponin T (hs-cTnT) level is associated with adverse ou

157 eferable when using high-sensitivity cardiac troponin T (hs-cTnT) levels in the diagnosis of acute my

158 Their high-sensitivity cardiac troponin T (hs-cTnT) levels were measured.

159 endpoints included high-sensitivity cardiac troponin T (hs-cTnT) on day 4, left ventricular (LV) rem

160 algorithm based on high-sensitivity cardiac troponin T (hs-cTnT) testing at presentation and again 1

161 we assessed whether high-sensitivity cardiac troponin T (hs-cTnT), a marker of subclinical myocardial

162 atriuretic peptide, high-sensitivity cardiac troponin T (hs-cTnT), and high-sensitivity cardiac tropo

163 eptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), and low-density lipoprotein choles

164 eptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), Cystatin-C (Cys-C), high-sensitivi

165 , measured by a new highly sensitive cardiac troponin T (hs-cTnT), may reflect ischemia without necro

166 nography and measurement of high-sensitivity troponin T (hs-TnT) and N-terminal pro B-type natriureti

167 High-sensitivity troponin T (hs-TnT) and N-terminal prohormone of brain n

168 High-sensitivity troponin T (hs-TnT) assays promise greater discriminatio

169 tic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT) can be used as surrogate markers and

170 The prognostic value of high-sensitivity troponin T (hs-TnT) elevation after elective percutaneou

171 the prevalence of elevated high-sensitivity troponin T (hs-TnT) in 298 patients with heart failure w

172 ate the prognostic value of high-sensitivity troponin T (hs-TnT) in addition to clinical risk factors

173 trasensitive tests to measure high-sensitive troponin T (hs-TnT) serum levels revealed the presence o

174 elationship between OSA and high-sensitivity troponin T (hs-TnT), cardiac structure, and CV outcomes

175 he prognostic importance of high-sensitivity troponin T (hs-TnT), N-terminal pro-brain natriuretic pe

176 merit with that of high-sensitivity cardiac troponin T (hs-TnT).

177 farction) evaluated high-sensitivity cardiac troponin-T (hs-cTnT) in a 1-hour acute myocardial infarc

178 h a biomarker (e.g. high sensitivity cardiac troponin T [hs-cTnT] or B-type natriuretic peptide [BNP]

179 rdial damage (using high-sensitivity cardiac troponin-T [hs-cTnT]) and with coronary heart disease (C

180 Human slow skeletal troponin T (HSSTnT) shares a high degree of homology wit

181 High-sensitivity troponin T (hsTnT) and N-terminal pro-B-type natriuretic

182 nknown if evaluation with a high-sensitivity troponin T (hsTnT) assay affects prognosis in this large

183 retic peptide (NTproBNP), and high-sensitive troponin T (hsTNT).

184 of the patients and high-sensitivity cardiac troponin T in 84.5%, with higher concentrations in those

185 ial measurements of high-sensitivity cardiac troponin T in clinical routine.

186 mited to the use of natriuretic peptides and troponin-T in patients with increased cardiovascular ris

187 ined as an absolute high-sensitivity cardiac troponin T increase of >/=14 ng/L from preoperative to p

188 Independent significant predictors of troponin T increase were higher New York Heart Associati

189 ease significantly over time, troponin I and troponin T increased moderately, and no consistent clini

190 ts for troponin I and long-term outcomes for troponin T (insufficient SOE).

191 For a third trait, cardiac troponin T, investigation of regulatory domains identifi

192 ntractile regulatory proteins troponin I and troponin T, is reduced during the first 3 weeks after bi

193 ion of the 14 C-terminal residues of cardiac troponin T leads to hypertrophic cardiomyopathy.

194 Twelve-hour troponin T, left ventricular ejection fraction, and perc

195 confidence limits (CL): 1.52 to 12.30), peak troponin T level (OR: 1.20; 95% CL: 1.08 to 1.34), and u

196 Bleeding event, peak troponin T level, and peripheral vascular disease predic

197 vel, hemoglobin A1c level, phosphorus level, troponin T level, log N-terminal pro-B-type natriuretic

198 nd-point was the proportion of patients with Troponin T levels >3xULN postprocedure (at 6 or 18-24 ho

199 Serum high-sensitivity cardiac troponin T levels and electrocardiograms were obtained e

200 Whether high-sensitivity cardiac troponin T levels are associated with adverse cardiovasc

201 However, changes in cardiac troponin T levels during the infusion did not differ bet

202 study was to examine the extent of change in troponin T levels in patients with non-ST-segment elevat

203 es, almost complete normalization of cardiac troponin T levels in serum and of left ventricular end d

204 ission and 15% of all cases with the highest troponin T levels on admission were ventilated.

205 yte, creatinine, creatine phosphokinase, and troponin T levels were normal.

206 patients with NSTE-ACS and elevated cardiac troponin T levels, an early invasive strategy has no ben

207 nfarct size (P<0.005) and a 61% reduction in troponin-T levels (P<0.05) in comparison with saline con

208 Troponin-T levels were measured at hospital admission, a

209 We also reconstituted mouse cardiac troponin T (McTnT) N-terminal deletion mutants, McTnT(1-

210 edural increases of high-sensitivity cardiac troponin T (mean: 9.9 ng/ml, range: 2.7 to 19.0 ng/ml vs

211 High levels of cardiac troponin T, measured by a highly sensitive assay (hs-cTn

212 o assess whether: 1) very small increases in troponin T, measured by a new highly sensitive cardiac t

213 rdiography, and concomitant high-sensitivity troponin-T measurement in patients with severe sepsis or

214 24-hour postoperative high-sensitive cardiac troponin T measurements and the respective changes were

215 re- and postoperative high-sensitive cardiac troponin T measurements demonstrated a majority of patie

216 6) with troponin I and 21.4% (n = 7319) with troponin T measurements.

217 Troponin-T measurements were available from 54 xenon pat

218 cardiograms and concomitant high-sensitivity troponin-T measurements were performed in a cohort of 10

219 Compared with the cardiac troponin T method, hsTnT detected 27% more ACS cases (P=

220 nT) and compared with a conventional cardiac troponin T method.

221 presenting different proteins (troponin I or troponin T), modifications (missense mutation, deletion,

222 In addition, two mouse cardiac troponin T mutants (TnT(1-44Delta) and TnT(45-74Delta))

223 in vivo, transgenic mice harboring the R92Q troponin-T mutation and wild-type littermates received a

224 f Drosophila cardiac tubes revealed that the troponin-T mutation prolongs systole and restricts diast

225 positive for the cardiac markers troponin I, troponin T, myosin heavy chain, and connexin-43.

226 Measures: Concentrations of high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, a

227 white blood cell count, fibrinogen, D-dimer, troponin T, N-terminal pro-brain natriuretic peptide, an

228 biomarkers of cardiac damage were measured (troponin T, N-terminal pro-brain natriuretic peptide, an

229 ence laboratory) measures of troponin level (troponin T or troponin I, as available).

230 plicing patterns (for example, human cardiac troponin T) or affects other aspects of RNA biology.

231 erences in creatine kinase release (P=0.92), troponin T (P=0.85), or cardiac MRI-assessed infarct siz

232 MVO patients had higher troponin T peak (P<0.0001), larger late gadolinium enhan

233 In contrast, patients with NR had higher troponin T peak (P=0.006) but similar late gadolinium en

234 no effects on phosphorylation of troponin I, troponin T, phospholamban, or myosin light chain-1 or -2

235 TPase, increased levels of phospholamban and troponin T phosphorylation, and reduced phosphorylation

236 Concomitant high-sensitivity troponin-T predicted mortality in univariate analysis (W

237 lective expression of EcSOD from the cardiac troponin-T promoter after systemic administration of AAV

238 The troponin-T promoter restricted gene expression largely t

239 superoxide dismutase (EcSOD) via the cardiac troponin-T promoter would protect the mouse heart agains

240 in the gene TNNT2, which encodes the cardiac troponin T protein itself.

241 in natriuretic peptide (R=0.69, P<0.001) and Troponin T (R=0.53, P=0.006).

242 rates in fully reconstituted WT and cardiac troponin T R92L and R92W thin filaments.

243 y outcomes included infarct size assessed by troponin T release and by cardiac MRI on day 2.

244 ylprednisolone significantly reduced cardiac troponin T release and the number of allograft infiltrat

245 myocardial damage evidenced by serum cardiac troponin T release in the rat and mouse cardiac allograf

246 m21G6 significantly reduced infarct size and troponin-T release, and led to marked preservation of ca

247 All available cases were analyzed for troponin-T release.

248 markers of cardiac (high-sensitivity cardiac troponin T), renal (creatinine and cystatin-C), and hepa

249 re-PCI troponin T fall, followed by post-PCI troponin T rise >20%.

250 n natriuretic peptide (pro-BNP), and cardiac troponin T showed significant linear trends for increase

251 The total loss of slow skeletal muscle troponin T (ssTnT encoded by TNNT1 gene) due to a nonsen

252 y more cardiomyocytes, determined by cardiac troponin-T staining, in the MI zone of the QHG213H hydro

253 myocardial perfusion imaging after negative troponin T tests and nondiagnostic ECGs.

254 tween or near residues 112 to 136 of cardiac troponin-T, the crucial TnT1 (N-terminal domain of tropo

255 oding cardiac troponin I (TNNI3) and cardiac troponin T (TNNT2) caused altered troponin protein stoic

256 cluding the Insulin Receptor (Insr), Cardiac Troponin T (Tnnt2), Lim Domain Binding 3 (Ldb3) RNAs in

257 roponin I (TNNI3p.98truncation ) and cardiac troponin T (TNNT2p.K217deletion ; also known as the p.K2

258 The independent predictive value of troponin T (TNT) after on-pump cardiac surgery was estab

259 Troponin T (TnT) and troponin I (TnI) are two evolutiona

260 The three isoforms of vertebrate troponin T (TnT) are normally expressed in a muscle type

261 Cardiac troponin T (TnT) is a highly sensitive cardiac biomarker

262 The thin filament protein troponin T (TnT) is a regulator of sarcomere function.

263 cardiomyocytes isolated from mice expressing troponin T (TnT) mutants (TnT-I79N, TnT-F110I, TnT-R278C

264 Three troponin T (TnT) mutants that cause hypertrophic, restri

265 In this study, polymer imprinted with troponin T (TnT) was assessed using electrochemical meth

266 The interference effect of troponin T (TnT), bovine serum albumin (BSA) and myoglob

267 als also showed negligible interference from troponin T (TnT), bovine serum albumin (BSA) and urea un

268 its, troponin C (TnC), troponin I (TnI), and troponin T (TnT).

269 tions in the TNNT2 gene that encodes cardiac troponin T (TnT).

270 ced expression of troponin I to 39% and 51%, troponin T to 64% and 53%, and troponin C to 73% and 97%

271 the binding of increasing concentrations of troponin-T to the immobilized antibodies on the ZnO surf

272 in-T, the crucial TnT1 (N-terminal domain of troponin-T)-tropomyosin-binding region, cause cardiomyop

273 Myosin-binding protein C, troponin T, tropomyosin and myosin regulatory light chai

274 -pro-B-type natriuretic peptide (NT-proBNP), troponin T (TropT) and C-reactive protein (CRP) predict

275 rrest of cardiomyocyte contraction either by troponin T type 2a (tnnt2a) MO or in weak atriumm58 (wea

276 An abnormal troponin T value of 14 ng per liter or higher did not id

277 diovascular disease in our study had cardiac troponin T values above the current myocardial infarctio

278 The effect of xenon on the change in the troponin-T values did not differ in patients with or wit

279 Troponin T was analyzed on admission, before PCI, and at

280 Elevated high-sensitivity troponin T was associated with an increased risk of card

281 n A(1c), detectable high-sensitivity cardiac troponin T was associated with subsequent CVD (myocardia

282 High-sensitivity cardiac troponin T was detectable (>/= 0.003 mug/L) in 45.5% of

283 Cardiac troponin T was detectable (>/=3.00 pg/mL) in 2794 partic

284 Troponin T was elevated in a substantial number of patie

285 Highly sensitive troponin T was lower at follow up (Baseline 38.8 pg/L, f

286 High-sensitivity cardiac troponin T was measured as a marker of myocardial injury

287 A periprocedural increase in troponin T was observed in 3.2% of the CHF procedures, i

288 The level of high-sensitive cardiac troponin T was significantly associated with preexisting

289 Troponin T was significantly increased in blood, and ech

290 The release of troponin-T was determined at arrival to hospital and at

291 Enhanced detection of troponin-T was found to correlate to the oxygen vacancie

292 Western blot analysis showed that troponin-T was indeed degraded during storage after HP t

293 Elevated levels of troponin I or troponin T were associated with higher risk for short-te

294 iuretic peptide and high-sensitivity cardiac troponin T were measured 1, 2, and 7 days after enrollme

295 ntricular structure and function and cardiac troponin-T were among the top predictors for incident he

296 in the interactions between CTnC and cardiac troponin T, which are known to be necessary for ATPase a

297 We measured cardiac troponin T with a highly sensitive assay (hs-cTnT) at 2

298 ro-brain natriuretic peptide (NT-proBNP) and troponin T with liver involvement and the presence of ne

299 t patients would have had a negative cardiac troponin T with older assays); and Group 4, those with h

300 re- and postoperative high-sensitive cardiac troponin T with the occurrence of major adverse cardiac